Composition combining thermal spring water and lactobacillus acidophilus extract and its activity for enhancing skin barrier and combating skin aging

Abstract

The present invention relates to a cosmetic and / or dermatological composition. The composition is characterized in that it comprises, in a physiologically acceptable medium, hot spring water having a mineral content of greater than 20 mg / l and an extract of Lactobacillus acidophilus at a concentration of between 1% and 10% by weight relative to the total weight of the composition. The invention also relates to the use of such a composition for protecting, enhancing and / or repairing the barrier function of the skin and reducing discomfort sensitive to the reactive skin or even atopic skin, for combating skin aging and for improving the microflora of the skin.

Description

Technical Field

[0001] The present invention relates to a cosmetic and / or skin product composition comprising a combination of hot spring water and a Lactobacillus acidophilus extract, and use of the composition for skin care. Background Art

[0002] The skin is a continuously renewing organ that covers the body surface and forms the interface between the organism and the external environment. Its purpose is to protect the body from external insults, but it also combats dehydration by limiting the diffusion of water.

[0003] The skin is therefore an important organ composed of several layers (dermis, proliferative layer and stratum corneum) that perform protective, sensory, immune, metabolic or thermoregulatory functions. Like other organs, the skin ages.

[0004] The appearance of the skin can change due to internal changes (intrinsic aging, disease, and hormonal changes, such as pregnancy) or external factors (environmental factors, such as pollution, sunlight, pathogens, temperature changes, etc.). These changes can lead to the appearance of wrinkles and fine lines, pigmentation defects, dryness or even dehydration of the skin, thinning of the epidermis, elastosis, spots, age spots, etc. Each of these changes affects not only the skin, but also the keratinized appendages, such as nails and hair.

[0005] While the entire structure of the skin plays an active role in the body's defense, this skin barrier is largely provided by the epidermis.

[0006] The epidermis is an epithelium subdivided into layers or strata, from the basal layer just above the dermis, through the stratum granulosum and spinosum, to the top stratum corneum.

[0007] The epidermis is essential for preventing the loss of water and other body components to the external environment and for protecting the body from various environmental insults. Its primary function is to protect the body from external threats by establishing a physical, chemical, biochemical, and immunological barrier to them while maintaining a certain capacity for exchange between the external and internal environments.

[0008] The highly compact structure of the stratum corneum forms a barrier against external causes of damage, rendering the skin impermeable. Lipids (polyunsaturated fatty acids, cholesterol, ceramides) and keratin in the intercellular cement ensure water tightness and slow down water evaporation from deeper layers. For this effect to be optimal, the stratum corneum must be completely intact: if it is overhydrated (for example, under occlusive patches), the skin becomes permeable in both directions; if it is dry, the barrier breaks down and becomes fragile.

[0009] The skin's hydration level is the result of a balance between water diffusion and evaporation. The margin for optimal hydration is very narrow: plus or minus 2% around the average of 13%. Once the skin's moisture content falls below 10%, it is considered dry.

[0010] If water evaporation is permanent, it is constantly renewed by the mechanism of diffusion. These losses are compensated by nutrition and water uptake by the skin: water from the bloodstream replenishes the water reserves in the dermis, which continue to diffuse into the upper layers of the skin.

[0011] Therefore, moisturizing the skin is essential for the skin's barrier function. Skin water can be found in different states: immobile water, which is bound to biomolecules; and mobile water, which can pass through the different layers of the epidermis.

[0012] The dermis is the skin's water reservoir, containing approximately 80% of the skin's moisture. It can store water because it is primarily composed of a proteoglycan gel (extracellular matrix) that encapsulates its constituent proteins (collagen, elastin, etc.). This gel is particularly composed of hyaluronic acid, which has the ability to bind water (up to 1000 times its weight), thereby retaining most of the water in the dermis. This large water reserve ensures the skin's "tightness."

[0013] A small fraction of this water is called "mobile water." It is able to penetrate the upper layers of the epidermis by passive diffusion. It also moisturizes the corneocytes, which, in addition to being rich in keratin, also contain their own natural moisturizing factor (NMF), composed of several molecules (such as urea, amino acids derived from the degradation of filaggrin, lactic acid, sugars, and mineral salts) that have water-retaining properties.

[0014] NMF constitutes up to 20%-30% of the dry matter of the stratum corneum, helping to keep the stratum corneum moisturized, preventing the skin from feeling dry and keeping the skin soft and supple.

[0015] Skin dryness increases with age due to a decrease in NMFs. Similarly, any mechanical or chemical alteration of keratinocytes causes NMFs to leak out of the cells, reducing their ability to retain water. After washing the skin with soap, the levels of NMF components decrease. This reduction in NMFs dries out the skin and impairs its barrier function. With less protection, the skin becomes significantly more susceptible to damage from irritants. Therefore, NMFs are considered essential components for regulating epidermal homeostasis and need to be strengthened.

[0016] NMF keeps the stratum corneum hydrated and the skin soft.

[0017] When barrier function is disrupted, the epidermis triggers different signaling pathways to restore the skin's normal state. Lipid secretion is stimulated, and filaggrin is degraded into NMFs. These two actions occur simultaneously to restore barrier function. Therefore, a decrease in filaggrin reveals an altered skin barrier.

[0018] This protein's primary function is to form the skin barrier. It is responsible for the aggregation and compaction of intermediate keratin filaments, playing a role in the flattening of cells (keratinocytes). Intermediate keratin filament bundles aggregated by filaggrin bind to structural proteins through the action of transglutaminase.

[0019] Filaggrin is considered one of the so-called "youth proteins," like collagen and elastin.

[0020] In the stratum corneum, its role is twofold: it both helps retain water in the skin and helps protect the epidermis from damaging rays of the sun.

[0021] It is a marker of improved epidermal or keratinocyte differentiation. Furthermore, since lipids are synthesized in keratinocytes during this epidermal differentiation, filaggrin is also involved in the metabolism and organization of skin lipids (lipid bilayer).

[0022] According to the literature, 27.5% of American Caucasians, 48% of Europeans, 31.4% of Chinese, and 20% of Japanese with atopic dermatitis have mutations in the filaggrin gene. Approximately fifty loss-of-function mutations have been identified.

[0023] Nearly half of people with the most severe form of eczema are thought to have filaggrin deficiency, and patients with a genetic mutation in the gene are three times more likely to develop atopic dermatitis.

[0024] Indeed, mutations in the filaggrin gene interfere with the skin's ability to act as a barrier, making it more susceptible to allergies and infections. Furthermore, filaggrin deficiency in atopic dermatitis is associated with increased colonization by Staphylococcus aureus.

[0025] Therefore, filaggrin is essential for the formation and function of the skin barrier. Mutations in the filaggrin gene lead to skin disorders and increase the risk of developing conditions such as atopic dermatitis, which is characterized by chronic eczema, severe itching, and dry skin (xerosis).

[0026] Collagen production also declines with age. Starting at age 30, our skin loses an average of 1% collagen per year. As a result, the skin becomes fragile, withers, and loses its firmness.

[0027] However, repeated use of certain topical medications (dermocorticoids, retinoids, etc.) is known to dry out the skin, and once the skin is weakened, it cannot retain water properly.

[0028] Pathological factors such as changes in the skin barrier (dermatitis, burns, etc.) can also accelerate water loss.

[0029] Finally, when water intake is insufficient, skin dehydration occurs.

[0030] Water is extremely important to the skin. Therefore, it is an essential ingredient in cosmetics, acting both as a solvent and a moisturizer.

[0031] There are two main ways to increase skin hydration:

[0032] - Reduce water evaporation, and

[0033] -Increases water binding.

[0034] When a cosmetic product is formulated, it must maintain the integrity of the skin while being pleasant for the consumer to use (texture, scent, color, etc.) It must also match the pH of the skin.

[0035] Hydration can be easily restored by temporarily using a richer skin-makeup care product that meets the skin's needs.

[0036] The following types of substances are used in preparations:

[0037] - hydrophobic film formers, which remain on the skin surface after the aqueous phase of the emulsion has evaporated. They form an impermeable barrier that is somewhat closed and reduces the evaporation of inherent water. Illustrative examples include petrolatum, paraffin, beeswax, lanolin, cetyl and stearyl alcohols, fatty alcohols (caprylyl glycol, behenyl alcohol, cetearyl alcohol, octyldodecanol), silicones (cyclohexasiloxane, dimethicone), squalane, synthetic fatty esters (cetearyl isononanoate) and fatty acids (stearic and palmitic acids, lauroyl lysine), triglycerides (apricot kernel oil, sweet almond oil, soybean oil) and shea butter;

[0038] - intercellular cohesive correctors, which are incorporated into the intercellular spaces of corneocytes to restore cohesion between cells and limit water diffusion. Illustrative examples include ceramides, phospholipids, polyunsaturated fatty acids: gamma-linolenic acid (borage oil, camellia oil), linoleic acid (safflower oil, evening primrose oil);

[0039] Hydrophilic film-forming agents, which have a high ability to bind water within the stratum corneum. They act like a "gel" to retain water on the skin's surface, enhancing the moisturizing ability of other associated active ingredients. Illustrative examples include glycosaminoglycans (hyaluronic acid), collagen, chitosan, galactomannans, polyvinyl alcohol, etc.

[0040] - Hygroscopic "moisturizing" substances that capture water from the environment and deliver it to the skin. They are widely used and need to be combined with a lipophilic agent. Illustrative examples include glycerol, glycerol (stearate), sorbitol, and propylene glycol.

[0041] These substances can be used to form emulsions. Their aqueous phase consists essentially of water, the primary ingredient in the composition of skin cosmetics. Typically, demineralized, decontaminated water is used as a solvent. Alternative thermal waters offer the potential to benefit from their unique physical and chemical composition, making them active ingredients in their own right, rather than simply solvents. However, their use requires complex formulations with a lipophilic phase to be effective, as the minerals must come into contact with the skin, a hydrophobic surface.

[0042] However, the presence of surfactants and emulsifiers (such as polyethylene glycol, polysorbate, potassium alkyl phosphates, etc.) is necessary to ensure phase miscibility and emulsion stability. Various texturing agents are also incorporated.

[0043] In addition, in order to provide a biological solution for protecting the barrier function of the skin and repairing the barrier function of the skin after external damage, patent document EP2986347 discloses a skin product composition for external use, which comprises a combination of a culture supernatant and a cell lysate, the supernatant and the lysate being derived from a culture of Lactobacillus pentosus (and more particularly the strain Lactobacillus pentosus CNCM 1-4730, as deposited with the National Collection of Microorganisms (CNCM) on April 4, 2013 under the Budapest Treaty), for treating irritated or inflamed skin, the supernatant and the cell lysate being derived from a culture of Lactobacillus pentosus in the stationary phase, after centrifuging the culture medium to obtain a supernatant and a biomass, the supernatant and the biomass are separated, the biomass is completely lysed to obtain a lysate, and the supernatant and the lysate are mixed at a weight ratio of supernatant to lysate of 1 to 50, the combination being present at a concentration of 0.1% to 10% by weight relative to the total weight of the composition.

[0044] The authors have demonstrated that in order to have such properties, the culture extract must combine both the supernatant and the cell lysate from the culture, a combination that makes it possible to bring together proteins, peptides, polysaccharides and short-chain amino acids and organic acids, and more generally all the compounds that form the bacterial cells, and metabolites produced by Lactobacillus pentosus (L. pentosus), which, in combination, improve the barrier function of the stratum corneum by providing nutrients for the NMF or accelerate its recovery when it is damaged.

[0045] Also known is document WO 2022 / 013897, which discloses a skin care composition comprising a mixture of 0.1% to 1% (w / w) of a lysate from the fermentation of Lactobacillus acidophilus, Lactobacillus casei, and Lactobacillus plantarum, and a lysate of Streptococcus thermophilus. This is a skin care composition that is somewhere between skin care and color foundation, intended for those who want a "hybrid" solution that is half skin care, half makeup, to rebalance the skin, increase skin hydration and elasticity, and reduce skin discoloration.

[0046] Bifidobacterium longum lysate has also been shown to benefit skin sensitivity by inhibiting the release of neurotransmitters such as substance P and improving skin barrier function. Other examples of lactic acid bacteria extracts include Streptococcus salivarius, which increases ceramide levels in the skin (Bifidobacterium longum lysate, a new ingredient for reactive skin, Audrey Guéniche et al., L'Oreal Research, 2009).

[0047] Lactobacillus ferments have also been used in cosmetics, but primarily as skin care agents and antimicrobial preservatives.

[0048] Document CN106860284 describes an anti-wrinkle composition, which is composed of the following raw materials, which are combined for their significant antioxidant effects, and are calculated by weight as follows: 0.5% ginseng extract, 0.6% arbutin, 0.3% glabridin, 0.2% snail protein powder, 0.3% licorice flavonoids solution, 0.5% trans-tetracycline acid, acid), 0.6% aloe vera extract, 0.8% yeast extract, 0.7% honeysuckle extract, 1.3% cyanocobalamin, 1.2% cellulase, 1.5% lactobacillus acidophilus, 1.2% euphorbia extract, 1.5% salvia miltiorrhiza extract, mugwort leaf extract, 1.6% atractylodes extract, 1.3% gynostemmapentaphylla extract, 1.5% loofah extract, 1.7% gentiana extract, 1.1% clove extract, 1.2% licorice root extract, 0.8% vitamin C, 0.9% chamomile extract, 1% centella asiatica extract, 0.9% angelica extract, 1% lily extract, 1.1% cornflower extract, 1.5% caprylic triglyceride, 1.2% frankincense, and 71.4% ionized water.

[0049] Liquid SF is known, for example, as a probiotic derived from the fermentation of Lactobacillus acidophillus, which is known to moisturize the skin by reducing water loss.

[0050] Thermal waters are also known for their beneficial effects on the skin. Naturally rich in minerals and trace elements, these waters have moisturizing, soothing, remineralizing, anti-free radical, anti-inflammatory, healing, anti-irritant and decongestant properties, making them ideal for addressing many skin disorders (dryness, discomfort, irritation, etc.).

[0051] However, no two hot spring waters are the same. In fact, depending on the source from which the hot spring water is drawn, the hot spring water will not have the same composition as hot spring water drawn from another source.

[0052] For example, Jonzac thermal water is known and used for its regenerative (strengthening the skin barrier), anti-inflammatory (limiting sensitivity and reactions associated with inflammation), soothing (calming the skin and limiting redness) and moisturizing (enhancing the skin's natural hydration) properties.

[0053] Technical issues

[0054] In view of the above, one problem proposed by the present invention is to provide a new biological solution for protecting the barrier function of the skin and repairing the barrier function of the skin, for example after external damage.

[0055] Unexpectedly, the applicant has demonstrated that the synergistic effect of thermal water and postbiotics makes it possible to completely reduce the degradation of filaggrin, thereby maintaining the barrier function of the skin, and also induces an increase in the expression of type I collagen. In addition, this protective or restorative effect halved the proliferative response and demonstrated good anti-aging activity.

[0056] Technical Solution

[0057] A first object of the solution to this problem is a cosmetic and / or dermatological composition, characterized in that it contains, in a physiologically acceptable medium, thermal water having a mineral content greater than 20 mg / L and an extract of Lactobacillus acidophilus in a concentration between 1% and 10% by weight of the total weight of the composition.

[0058] It also encompasses the use of the composition according to the invention for protecting, strengthening and / or repairing the barrier function of the skin, for combating skin aging and for improving the microflora of the skin.

[0059] The invention and its advantages will be better understood after reading the following description and non-limiting examples. BRIEF DESCRIPTION OF THE DRAWINGS

[0060] The invention and its advantages will be better understood after reading the following description and non-limiting embodiments, with reference to the accompanying drawings, in which:

[0061] Figure 1 Epidermal hyperplasia after stripping at D8 is shown by measuring the epidermal thickness of different batches of human skin explants tested in Example 1 .

[0062] Figure 2 The inhibitory effect of the products tested in Example 1 on D8 peeling-induced epidermal hyperplasia is shown.

[0063] Figure 3 Shown is the staining of filaggrin in the stratum corneum of different batches of human skin explants tested in Example 1 .

[0064] Figure 4 The percentage of surface area occupied by filaggrin in the stratum corneum of the different batches of human skin explants tested in Example 1 is shown.

[0065] Figure 5 Shown is the staining of type I collagen in the papillary dermis of different batches of human skin explants tested in Example 1 .

[0066] Figure 6Shown is the percentage of surface area occupied by type I collagen in the papillary dermis of the different batches of human skin explants tested in Example 1.

[0067] Figure 7 The following table summarizing the results obtained in different batches of human skin explants tested in Example 1 with respect to cell viability, epidermal thickness, filaggrin expression and type I collagen expression is shown.

[0068] Figure 8 The following table summarizing the comparative expression values ​​of filaggrin and type I collagen in different batches of human skin explants tested in Example 1 is shown.

[0069] Figure 9 Shown is a linearization plot of the percentage (%) of DPPH reduction as a function of trolox concentration (mg / L).

[0070] Figure 10 Shown are the free radical scavenging activities of a combination of 2% Lactobacillus acidophilus extract + 0.5% distilled water and a combination of 2% Lactobacillus acidophilus extract + 0.5% Jonzac thermal water in terms of DPPH reduction percentage (%). DETAILED DESCRIPTION

[0071] The present invention relates to a cosmetic and / or dermatological composition, characterized in that the composition comprises, in a physiologically acceptable medium, thermal water having a mineral content greater than 20 mg / L and an extract of Lactobacillus acidophilus at a concentration between 1% and 10% by weight of the total weight of the composition.

[0072] Physiologically acceptable media means media that are suitable for use in contact with human and animal cells, particularly with epidermal cells, without toxicity, irritation, undue allergic response, etc., and are commensurate with a reasonable benefit-risk ratio.

[0073] This physiologically acceptable medium may comprise excipients known and used in the cosmetic and dermatological fields.A person skilled in the art will carefully choose the physiologically acceptable medium in such a way that it does not impair the attractive properties of the composition according to the invention.

[0074] Thermal spring water means naturally mineralized spring water having a mineral content greater than 20 mg / L, preferably greater than 150 mg / L, more preferably greater than 1000 mg / L, even more preferably greater than 5000 mg / L, and even more preferably greater than 7000 mg / L.

[0075] Preferably, the thermal water is selected from the thermal waters of Jonzac, Rochefort, Avène, La Roche Posay, Uriage, Saint Gervais, Gamarde, Fumades, Cauteret, Evaux, Vichy, more preferably the thermal waters of Jonzac and Rochefort, even more preferably the thermal water of Jonzac.

[0076] The thermal water preferably used is a polymetallic sulfated calcium-containing mixed thermal water containing sodium chloride and magnesium, which is hypermineralized with a mineral content of at least 5000 mg / L, for example about 7000 mg / L, which essentially contains calcium and magnesium, as well as silicon, strontium, boron, lithium and manganese, and is hypotonic, almost isotonic.

[0077] Preferably, the thermal water used is Jonzac thermal water.

[0078] The Jonzac thermal water is more specifically a hypermineralized water rich in sulfides, mixed sulfates, sodium chloride, trace elements, with a mineral content exceeding 6500 mg / L, for example, approximately 7000 mg / L. Among the minerals, we mainly find calcium (Ca2+), magnesium (Mg2+) and strontium (Sr).

[0079] Jonzac thermal water is superheated (appearing at 62°C), bacteriologically pure and isotonic, with a pH of 6.95.

[0080] The composition according to the invention preferably comprises thermal water in a concentration by weight of between 0.5% and 99.5%, for example 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, preferably between 5% and 50%, more preferably between 10% and 35%, even more preferably 20% or 30%, relative to the total weight of the composition.

[0081] The composition according to the invention comprises postbiotics, ie preparations of non-living microorganisms and / or components thereof capable of conferring, inter alia, a health benefit.

[0082] Postbiotics differ from probiotics in that the latter are inactivated after the fermentation process. Therefore, postbiotics can correspond to whole microbial cells or only certain components or metabolites.

[0083] The composition according to the invention comprises a skin postbiotic, namely an extract of Lactobacillus acidophilus.

[0084] Lactobacillus acidophilus is a Gram+, non-spore-forming, rod-shaped lactic acid bacterium with rounded ends. It is non-motile and occurs singly, in pairs, or in short chains.

[0085] It is a bacterium that grows optimally at temperatures between 35° C. and 40° C., but it can grow up to 45° C. The optimal pH for its growth is between 5.5 and 6.

[0086] Most strains are aerotolerant, but growth is optimal under microaerobic or even anaerobic conditions.

[0087] The Lactobacillus acidophilus extract preferably used is a Lactobacillus acidophilus cell lysate derived from fermentation of Lactobacillus acidophilus.

[0088] According to an advantageous embodiment, the cell lysate of Lactobacillus acidophilus is obtained by fermenting Lactobacillus acidophilus in a medium containing ammonium sulfate, magnesium sulfate, disodium phosphate (minerals) and natural yeast autolysate, followed by controlled lysis in the presence of lysozyme derived from papaya (Carica papaya), and removing the biomass after filtration and recovering the cell lysate.

[0089] The Lactobacillus acidophilus extract used is, for example, an extract of the strain Lactobacillus acidophilus ATCC 314.

[0090] The composition according to the invention preferably comprises an extract of Lactobacillus acidophilus in a concentration between greater than 1.5% and 10% by weight, more preferably between 2% and 10% by weight, such as 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, still more preferably between 2% and 5%, even more preferably 2% of the total weight of the composition.

[0091] Preferably, the composition according to the invention further comprises, alone or in combination, hyaluronic acid and its derivatives; hydroxyproline and its derivatives, such as dipalmitoylhydroxyproline; hydrolyzed lupin protein; algae extracts, such as aqueous extracts of protein-rich brown algae such as Fucus vesiculosus and Laminaria japonica, oily extracts of green algae such as Pterocarpus sylvestris or Chlorella vulgaris, or extracts of red algae such as Jania rubens; oligosaccharides (prebiotics); zinc PCA; mallow or chamomile flower water; witch hazel extract; Centella asiatica extract; aloe vera extract / aloe vera juice; ceramides, such as N-oleoyl-phytosphingosine (or ceramide NP); phytosphingosine; sodium carrageenan; dextrin; phytic acid; tocopherol; buckwheat wax; shea butter; castor oil; vegetable squalane; glycerin.

[0092] More preferably, the composition according to the present invention further comprises, alone or in combination, hyaluronic acid and its derivatives, mallow flower water, aloe extract / aloe juice, Centella asiatica extract, red algae extract such as Coriander leaf algae, sodium carrageenan, phytosphingosine, dextrin, phytic acid, tocopherol, buckwheat wax, shea butter, castor oil, vegetable squalane, and glycerin.

[0093] Preferably, the composition according to the invention is in a form suitable for topical administration.

[0094] Illustrative examples of topical formulations according to the present invention include creams (optionally pigmented), oil-in-water (O / W) emulsions, water-in-oil (W / O) emulsions, gels, gel creams, water, skin or lip balms, ointments, serums, eye and lip liner products, micellar waters, facial masks or cleansers.

[0095] Another object of the present invention relates to a composition according to the invention for protecting, strengthening and / or repairing the barrier function of the skin and reducing the discomfort of sensitive to reactive and even atopic skin.

[0096] Protecting, strengthening and / or repairing the barrier function of the skin means, for example, improving skin hydration, i.e., any improvement in the appearance of changes in the skin caused by dehydration (e.g., dryness, tightness); as well as soothing discomfort and reducing reactivity in order to help prevent the onset of visible skin reactions, particularly in sensitive to reactive skin or even atopic skin.

[0097] The composition according to the invention is also intended to combat skin aging by enhancing skin firmness, in particular for normal to sensitive skin.

[0098] Signs of skin aging include all age-related changes in the skin's appearance, such as fine lines and wrinkles, cracks, eye bags, dark circles, dryness, loss of skin elasticity, firmness and / or tone, but also all internal changes in the skin that do not necessarily produce visible changes, such as thinning of the skin or any internal damage to the skin.

[0099] The composition according to the invention is also used to improve the skin microflora.

[0100] By way of illustrative example, the compositions according to the present invention can help make the skin less susceptible to penetration by allergens, bacteria, viruses and inflammation, thereby preventing the progression of skin pathologies such as atopic dermatitis, preventing the appearance of premature aging and wrinkles, and improving skin hydration.

[0101] Example

[0102] The invention will now be illustrated with the aid of the following examples:

[0103] Example 1: Evaluation of the activity of Jonzac thermal water, Lactobacillus acidophilus and their combination on human skin explants price

[0104] The aim of this two-phase study was to evaluate the anti-aging and epidermal barrier-enhancing effects of the two products and their synergistic effects in ex vivo human skin explants.

[0105] The first ex vivo stage recreates the application of the product on the skin.

[0106] The second histological phase enables the evaluation of the evolution of biological parameters by staining and immunolabeling.

[0107] Activity was assessed by:

[0108] - Assessment of cell viability after Masson's trichrome staining and measurement of epidermal thickness,

[0109] - Immunostaining for filaggrin, and

[0110] -Immunostaining for type I collagen.

[0111] Test the following products:

[0112] - P1 = Jonzac thermal water; and

[0113] - P2 = Lactobacillus acidophilus extract.

[0114] It should be understood that in the following examples, P1 refers to Jonzac thermal water, and P2 refers to Lactobacillus acidophilus extract.

[0115] At D0, dilute products P1 and P2 in sterile distilled water as follows:

[0116] - Batch P1 = 20% of P1;

[0117] - Batch P2 = 2% of P2; and

[0118] - Batch P3 = 20% of P1 + 2% of P2.

[0119] The prepared product was stored at 4°C during the ex vivo phase of the study.

[0120] Stage 1: Explant preparation

[0121] For the ex vivo phase of the study, 18 human skin explants were prepared from abdominoplasty procedures in 69 year old phototype II Caucasian women, measuring 12 ± 1 mm in diameter, 12 of which had undergone 10 peels (batches S and S'x') (reference number P2660-AB69).

[0122] Exfoliation is a mechanical skin stimulation model that involves gradually peeling off the superficial part of the epidermis, the stratum corneum. Skin stimulation is achieved by continuously applying and removing an adhesive tape over the same skin area.

[0123] Explants were grown in acclimation medium at 37°C in a humidified atmosphere enriched with 5% CO2.

[0124] Damage to the epidermal barrier

[0125] At D0, just before product application, explants from batches S and S'x' were stripped 10 times with tape.

[0126] Explant distribution

[0127] The explants were divided into 6 batches as follows:

[0128] Table 1:

[0129]

[0130] Apply product

[0131] At D0, D2, D3 and D6, the test products P1, P2 and P3 were added at 2 μL / 1 cm 2 Explants (approximately 2 mg / cm 2 ) and applied topically using a spatula.

[0132] Explants from control batches received no treatment other than refreshing the medium.

[0133] Half of the culture medium (1 mL / well) was renewed on D2, D3, and D6.

[0134] Harvest

[0135] At D0, 3 explants were harvested from batch T0. Each sample was cut in half, one half was frozen at -80°C at optimal cutting temperature (OCT), and the other half was fixed in formalin.

[0136] On D8, 3 explants were harvested from each batch and processed in the same manner as described above on D0.

[0137] Phase 2: Histological processing

[0138] The samples were fixed in buffered formalin for 24 hours, then dehydrated using a Leica PEARL automatic dehydrator and paraffin-impregnated. The samples were embedded using a Leica EG 1160 embedding station.

[0139] 5 μm sections were cut using a Leica RM 2125 Minot microtome and mounted on On histological slides.

[0140] Microscopic observations were performed by light microscopy using a Leica DMLB, Olympus BX43, or Olympus BX63 microscope.

[0141] Images were captured using an Olympus DP72 or DP74 camera and cellSens software.

[0142] 1. Cell Viability

[0143] Cell viability of epidermal and dermal structures was assessed on paraffin sections after staining with a variant of Goldner's Masson's trichrome. This was assessed by microscopy. All batches underwent this procedure.

[0144] 2. Epidermal Thickness Measurement

[0145] On each image from Masson's trichrome staining, epidermal thickness was measured at several points using the Olympus CellSens software measurement module.

[0146] For all batches, three thickness measurements were performed on each image, corresponding to 27 measurements per batch. This was done for all batches.

[0147] 3. Immunostaining of Filaggrin

[0148] Paraffin sections were immunostained for filaggrin using an anti-filaggrin monoclonal antibody (Santa Cruz, sc-66192, clone AKH1) diluted 1:100 in 0.3% PBS-BSA for 1 h at room temperature and visualized with Alexa Fluor AF488 (Life Technologies, reference A11008). Cell nuclei were counterstained with propidium iodide. Immunostaining was assessed by microscopic observation. All batches underwent this procedure.

[0149] 4. Immunostaining of Type I Collagen

[0150] Type I collagen was labeled on frozen sections overnight at room temperature with a polyclonal anti-type I collagen antibody (Abcam, ab138492-1001) diluted 1:800 in 0.3% PBS-BSA and revealed with AlexaFluor AF488 (Lifetechnologies, reference number A11008). Cell nuclei were counterstained with propidium iodide.

[0151] Immunostaining was assessed by microscopy and semi-quantified by image analysis for all batches.

[0152] result

[0153] 1. Cell Viability

[0154] The cell viability of all batches is shown in the table below:

[0155] Table 2:

[0156]

[0157] At D0, in the control batch (T0), cell viability was good in the epidermis and papillary dermis.

[0158] On D8, in the control batch (TJ8), cell viability in the epidermis was fair, and cell viability in the papillary dermis was good.

[0159] Damage to the epidermal barrier by 10 peels did not induce any changes in cell viability compared to the TJ8 control batch.

[0160] Effect of product on cell viability compared to batch SJ8:

[0161] - Product P1 induced no changes.

[0162] - Product P2 induced no changes.

[0163] - Product P3 did not induce changes.

[0164] Effect of product on cell viability compared to batch SP1J8:

[0165] - Product P3 did not induce changes.

[0166] Effect of product on cell viability compared to batch SP2J8:

[0167] - Product P3 did not induce changes.

[0168] 2. Measurement of Epidermal Hyperplasia

[0169] 2.1 Epidermal thickness

[0170] When the skin is weakened by skin peeling, several important phenomena are observed:

[0171] - Altered barrier function, as reflected by a decrease in certain markers of the stratum corneum, including filaggrin and lipids;

[0172] - The skin undergoes epidermal hyperplasia to restore optimal barrier function;

[0173] - Increased secretion of certain proinflammatory cytokines, including IL-1α.

[0174] When the products were tested on an ex vivo model of human skin weakened by exfoliation, their efficacy was evaluated according to several parameters, namely their ability to reduce epidermal hyperproliferation and their activity on the expression of barrier function markers.

[0175] Analysis of all batches for post-strip epidermal hyperplasia by measuring epidermal thickness is shown in the table below and in Figure 1 middle.

[0176] Table 3: Epidermal thickness (μm)

[0177] T0 TJ8 SJ8 SP1J8 SP2J8 SP3J8 average value 27.2 51.1 72.9 73.0 60.8 64.5 Standard deviation 3.5 5.8 7.3 7.8 6.5 7.9

[0178] At D0, on the T0 control batch, the epidermis measured an average of 27.2 μm.

[0179] On D8, on the TJ8 control batch, the epidermis measured an average of 51.1 μm.

[0180] Damaging the epidermal barrier through 10 peels induced epidermal hyperplasia, resulting in a significant 43%** increase in epidermal thickness compared to the TJ8 control batch.

[0181] Effect of product application on epidermal thickness compared to SJ8 control batch:

[0182] - Product P1 did not induce changes;

[0183] - Product P2 induced a significant 17%** reduction in peel-induced epidermal hyperplasia;

[0184] - Product P3 induced a significant 12%** reduction in peel-induced epidermal hyperplasia.

[0185] Effect of product application on epidermal thickness compared to the SP1J8 control batch:

[0186] - Product P3 induced a significant 12%** reduction in peel-induced epidermal hyperplasia.

[0187] Effect of product application on epidermal thickness compared to the SP2J8 control batch:

[0188] - Product P3 induced a significant increase of 6% #.

[0189] illustrate:

[0190] - not significant: ns;

[0191] -Significant: #, p < 0.1 (90%); *, p < 0.05 (95%); **, p < 0.01 (99%).

[0192] By stripping away the upper part of the stratum corneum, the barrier function of the skin has been altered.

[0193] After peeling (injury), the epidermis will accelerate the terminal differentiation of keratinocytes into corneocytes to rebuild the stratum corneum. To compensate for this loss of keratinocytes, the proliferation of the epidermal basal layer is activated (see the increase in thickness of the peeled control epidermis).

[0194] Product P1 (ETJ 20%) did not modify the proliferative response (epidermal thickness) following loss of barrier function.

[0195] Product P2 (2% Lactobacillus acidophilus extract) halved the proliferation response, suggesting that P2 has a protective effect against this response.

[0196] The combination of the two products halved the proliferative response and was therefore also protective.

[0197] 2.2 Inhibition of Hyperplasia

[0198] The percentage inhibition of peel-induced epidermal hyperplasia at D8 for the batches involved is shown in the table below and in Figure 2 middle.

[0199] Table 4: % Inhibition of Epidermal Hyperplasia

[0200] SP1J8 SP2J8 SP3J8 0％ 56％ 39％

[0201] Effects of product application on epidermal hyperplasia compared to the SJ8 control batch:

[0202] - Product P1 induced no changes.

[0203] - Product P2 induces a significant inhibition of 56%**.

[0204] - Product P3 induced a significant inhibition of 39%**.

[0205] illustrate:

[0206] -Not significant: ns

[0207] -Significant: #, p < 0.1 (90%); *, p < 0.05 (95%); **, p < 0.01 (99%).

[0208] 3. Filaggrin

[0209] Filaggrin staining in the stratum corneum of all batches is shown in Figure 3 middle.

[0210] At D0, in the T0 control batches, filaggrin staining was moderate to fairly pronounced in the stratum corneum.

[0211] At D8, in the TJ8 control batch, filaggrin expression was moderate to fairly evident in the stratum corneum.

[0212] Damage to the epidermal barrier by 10 peels (SJ8) induced a moderate decrease in filaggrin expression compared to the TJ8 control batch.

[0213] Effect of product application on filaggrin expression compared to the SJ8 control batch:

[0214] - Product P1 induces a slight increase;

[0215] - Product P2 induces a slight increase;

[0216] -Product P3 induced a moderate increase.

[0217] Effect of product application on filaggrin expression compared to the SP1J8 control batch:

[0218] - Product P3 induced a slight increase.

[0219] Effect of product application on filaggrin expression compared to the SP2J8 control batch:

[0220] - Product P3 induced a slight increase.

[0221] Filaggrin image analysis

[0222] For each batch of explants, the percentage of the area of ​​interest covered by staining (percent stained area) was determined by image analysis.

[0223] Comparison of staining area

[0224] The percentage of stained area (Area %) for each treatment was compared to the untreated condition.

[0225] Filaggrin image analysis was performed using cellSens software (Olympus).

[0226] Area analyzed per image: ROI including the stratum corneum.

[0227] Number of images analyzed per batch: 9.

[0228] Statistical test: Student's t test.

[0229] Batches analyzed: T0, on D8 [T, S, SP1, SP2, SP3].

[0230] The percentage of surface area occupied by filaggrin in the stratum corneum is shown in the table below and in Figure 4 middle.

[0231] Table 5: Filaggrin (area %)

[0232] T0 TJ8 SJ8 SP1J8 SP2J8 SP3J8 average value 69.3 91.5 65.4 83.1 77.4 88.6 Standard deviation 8.8 5.1 14.9 12.0 12.9 7.4

[0233] At D0, filaggrin occupied 69.3% of the stratum corneum area in the T0 control batch.

[0234] At D8, in the TJ8 control batch, filaggrin occupied 91.5% of the stratum corneum area.

[0235] Compared to the TJ8 control batch, 10 peelings damaged the epidermal barrier and induced a significant 29%** decrease in filaggrin expression.

[0236] Effect of product application on filaggrin expression compared to the SJ8 control batch:

[0237] - Product P1 induced a significant increase of 27%*;

[0238] - Product P2 induced a significant increase of 18% #;

[0239] - Product P3 induced a significant increase of 35%**.

[0240] Effect of product application on filaggrin expression compared to the SP1J8 control batch:

[0241] - Product P3 induced a non-significant increase of 7% ns.

[0242] Effect of product application on filaggrin expression compared to the SP2J8 control batch:

[0243] - Product P3 induced a significant increase of 14%**.

[0244] illustrate:

[0245] - not significant: ns;

[0246] -Significant: #, p < 0.1 (90%); *, p < 0.05 (95%); **, p < 0.01 (99%).

[0247] 4. Type I collagen

[0248] Staining of type I collagen in the papillary dermis of all batches is shown in Figure 5 middle.

[0249] At D0, type I collagen staining in the papillary dermis was fair to marked on the T0 control batches.

[0250] On D8, type I collagen expression in the papillary dermis was moderate to fairly pronounced in the TJ8 control batch.

[0251] In the TJ8 control batch, damage to the epidermal barrier by 10 peels did not induce any changes in type I collagen expression.

[0252] Effect of product application on type I collagen expression compared to the SJ8 control batch:

[0253] - Product P1 induces a slight increase;

[0254] - Product P2 did not induce changes;

[0255] - Product P3 induced a slight increase.

[0256] Effect of product application on type I collagen expression compared to the SP1J8 control batch: - Product P3 did not induce changes.

[0257] Effect of product application on type I collagen expression compared to the SP2J8 control batch: - Product P3 induced a slight increase.

[0258] Type I collagen image analysis

[0259] For each batch of explants, the percentage of the area of ​​interest covered by staining (percent stained area) was determined by image analysis.

[0260] Comparison of staining area

[0261] The percentage of stained area (Area %) for each treatment was compared to the untreated condition.

[0262] Type I collagen images were analyzed using cellSens software (Olympus).

[0263] The area analyzed for each image was the ROI encompassing the papillary dermis.

[0264] Number of images analyzed per batch: 9.

[0265] Statistical test: Student's t test.

[0266] Batches analyzed: T0, on D8 [T, S, SP1, SP2, SP3].

[0267] The percentage of surface area occupied by type I collagen in the papillary dermis is shown in the table below and in Figure 6 middle.

[0268] Table 6: Type I collagen (area %)

[0269] T0 TJ8 SJ8 SP1J8 SP2J8 SP3J8 average value 88.0 69.6 70.6 76.5 71.8 78.3 Standard deviation 4.0 7.5 8.0 6.0 6.3 7.9

[0270] At D8, type I collagen occupied 69.6% of the papillary dermis surface in the TJ8 control batch.

[0271] Damage to the epidermal barrier via 10 peels induced a non-significant 1% ns increase in type I collagen expression compared to the TJ8 control batch.

[0272] Effect of product application on type I collagen expression compared to the SJ8 control batch:

[0273] - Product P1 induced a significant increase of 8% #;

[0274] - Product P2 induces a non-significant increase of 2% ns;

[0275] - Product P3 induced a significant increase of 11% #.

[0276] Effect of product application on type I collagen expression compared to batch SP1J8:

[0277] - Product P3 induced a non-significant increase of 2% ns.

[0278] Effect of product application on type I collagen expression compared to batch SP2J8:

[0279] - Product P3 induced a significant increase of 9% #.

[0280] illustrate:

[0281] - not significant: ns;

[0282] -Significant: #, p < 0.1 (90%); *, p < 0.05 (95%); **, p < 0.01 (99%).

[0283] in conclusion

[0284] A summary of the results obtained is shown in Figure 7 and Figure 8 middle.

[0285] According to the experimental conditions described above, and compared with the control batch T or the stripped batch S at D8:

[0286] All tested products were well tolerated in ex vivo human skin explants after 8 days of treatment.

[0287] The 20% product "Ingredient 1: Jonzac Thermal Spring Water" (P1) induced a slight increase in filaggrin expression after peeling, thus demonstrating a skin barrier strengthening effect. It also induced a slight increase in type I collagen expression, reflecting anti-aging activity.

[0288] The 2% product “Ingredient 2: Lactobacillus acidophilus” (P2) induced a slight increase in filaggrin expression after peeling, associated with a decrease in epidermal thickness (-17%**), thus highlighting a good skin barrier strengthening activity.

[0289] The combination of 20% "Ingredient 1: Jonzac Thermal Spring Water" (P1) and 2% "Ingredient 2: Lactobacillus acidophilus" (P2) induced an increase in filaggrin expression after peeling, which correlated with a decrease in epidermal thickness (-12%**), thus highlighting good skin barrier strengthening activity. This combination also induced a slight increase in type I collagen expression, reflecting good anti-aging activity.

[0290] The combination of 20% of "ingredient 1: Jonzac thermal water" (P1) and 2% of "ingredient 2: Lactobacillus acidophilus" (P2) has an additional effect on the enhancement of the barrier function and the expression of filaggrin and type I collagen.

[0291] Interpretation of epidermal thickness results: By stripping the upper part of the stratum corneum, the barrier function of the skin is impaired.

[0292] In response to this loss of barrier function, filaggrin is broken down into amino acids, which strengthen the NMF (Natural Moisturizing Factor) and bind large amounts of water.

[0293] At the same time, the epidermis accelerates the terminal differentiation of keratinocytes into corneocytes to rebuild the stratum corneum. To compensate for this loss of keratinocytes, the proliferation of the epidermal basal layer is activated.

[0294] Product P1 halved the degradation of filaggrin, thereby partially compensating (or repairing) the skin's barrier function. Furthermore, it did not alter the proliferative response (epidermal thickness) following loss of barrier function.

[0295] Product P2 halved the degradation of filaggrin, thereby partially compensating (or repairing) the skin's barrier function. Furthermore, this protective or restorative effect halved the proliferative response.

[0296] The combination of these two products completely reduced the degradation of filaggrin, thereby preserving the skin's barrier function. Furthermore, this protective or restorative effect halved the proliferative response.

[0297] Example 2: W / O emulsion

[0298]

[0299] Example 3: O / W emulsion

[0300]

[0301] Example 4: Micellar Water

[0302]

[0303] Example 5: Care gel / makeup remover

[0304]

[0305] Example 6: Gel Cream

[0306] Example 7: Evaluation of the anti-freeze activity of the combination of active ingredients using the DPPH (1,1-diphenyl-2-picrylhydrazyl) test Base activity

[0307] The aim of this study was to evaluate the anti-free radical potential of a combination of Lactobacillus acidophilus extract and Jonzac thermal water.

[0308] The anti-radical activity of the investigated products was evaluated by measuring the reduction rate of the DPPH radical in the presence of the product. The reduction rate of the DPPH (1,1-diphenyl-2-picrylhydrazyl) radical was assessed by measuring the change in the absorbance (abs) of the DPPH solution in the presence of the test product. DPPH is a stable colored radical. Reduction of the DPPH radical by a 1-1 atom donor results in the formation of colorless 1,1-diphenyl-2-picrylhydrazyl (DPPH-H). The reaction mixture then changes from dark purple to light purple, and can even become colorless for the strongest antioxidants.

[0309] After 24 h of incubation in the presence of the test product in DPPH solution (0.126 mM in ethanol), the absorbance of the solution was measured at 517 nm.

[0310] The percentage reduction of DPPH was calculated using the following formula:

[0311] DPPH reduction % = ((Abs reference - Abs test element) / Abs reference) * 100, where:

[0312] AbsRef = solvent absorbance; and

[0313] AbstestElement = absorbance of the test element.

[0314] The concentration of the test element that gives 50% DPPH reduction (IC50) is determined. This reflects the anti-radical activity of the test element.

[0315] The activity of the test elements was compared with that of the well-known anti-radical active ingredient Trolox.

[0316] The following four products were tested:

[0317] - A combination of 2% Lactobacillus acidophilus extract + 0.5% distilled water;

[0318] - A combination of 2% Lactobacillus acidophilus extract + 0.5% Jonzac thermal water;

[0319] - Jonzac thermal water only; and

[0320] - Trolox (positive control).

[0321] The results of the DPPH test thus obtained are presented in the table below and the linearization of the DPPH reduction % as a function of trolox concentration is shown in Figure 9 middle.

[0322] Table 7: DPPH test results using Trolox

[0323] Concentration (mg / L) refer to 0.625 1.25 2.5 3.75 5 DPPH reduction% 4.969 9.078 21.548 36.550 48.256

[0324] use Figure 9 The equation of the line (ax+b) shown in FIG5 was used to determine the IC50 of trolox, which corresponds to the effective concentration that reduces DPPH activity by 50%, according to the following formula: IC50 (mg / L) = (50-b) / a.

[0325] This gave the following value: IC50 trolox = 5.168 mg / L.

[0326] This control passed the test.

[0327] For the Jonzac Spring Water test, the following final concentrations (% w / v) were analyzed. The results of the DPPH test are shown in the table below.

[0328] Table 8: DPPH test results using Jonzac hot spring water

[0329] Concentration (% w / v) refer to 2.5 2 1.5 1 0.5 DPPH reduction% / -2.676 -2.793 -1.784 -0.698 -1.474

[0330] For the test using the combination of 2% Lactobacillus acidophilus extract + 0.5% Jonzac thermal water, the test elements were tested at the following final concentrations (% w / v). The results thus obtained are shown in the table below.

[0331] Jonzac thermal water alone does not have anti-free radical properties.

[0332] Table 9: DPPH test results using a combination of 2% Lactobacillus acidophilus extract + 0.5% Jonzac thermal water

[0333]

[0334] In order to compare the antioxidant capacity, Jonzac thermal water was replaced by distilled water at the following final concentrations (% w / v): The combination of 2% Lactobacillus acidophilus extract + 0.5% distilled water was tested with DPPH and the results obtained are presented in the table below.

[0335] Table 10: DPPH test results using a combination of 2% Lactobacillus acidophilus extract + 0.5% distilled water

[0336]

[0337] The anti-free radical ability of the combination of Jonzac thermal water and Lactobacillus acidophilus extract was evaluated by comparing it with the anti-free radical ability of the combination of distilled water and Lactobacillus acidophilus extract. The results are shown in Figure 10 middle.

[0338] A statistical test (Student's t-test) was performed to assess the significance of the difference in free radical scavenging ability between the two combinations. The Student's t-test gives the probability that the two batches are significantly different. If p < 0.1 (#), i.e., the probability that the two batches are significantly different is 90%, or p < 0.05 (*), i.e., the probability that the two batches are significantly different is 95%, or p < 0.01 (**), i.e., the probability that the two batches are significantly different is 99%, then the difference between the two batches is significant.

[0339] The results obtained showed that the combination of Lactobacillus acidophilus extract and distilled water exhibited a DPPH radical scavenging effect at the tested concentrations, and the DPPH reduction percentage was 61.363%, which was greater than 50%.

[0340] In contrast, at the concentrations tested, the combination of Lactobacillus acidophilus extract and Jonzac thermal water (instead of distilled water) showed a DPPH radical scavenging effect, with a DPPH reduction percentage of 64.885%, which is greater than 50%.

[0341] The Student's t-test obtained gave a value of p=0.013, ie p<0.05 (*), which indicates that there is a 95% probability that the two batches tested are significantly different.

[0342] In conclusion, under the same conditions, the addition of Jonzac thermal water (used at a concentration of at least 0.5%) significantly improved the antioxidant effect of Lactobacillus acidophilus extract (used at a concentration of at least 2%) compared to distilled water. There was a significant synergistic effect of +5.67% (p<0.05).

Claims

1. A cosmetic and / or skin care product composition, characterized in that The composition comprises, in a physiologically acceptable medium, thermal water having a mineral content greater than 20 mg / L and an extract of Lactobacillus acidophilus at a concentration between 1% and 10% by weight of the total weight of the composition.

2. The composition according to claim 1, characterized in that The thermal spring water is selected from the thermal spring waters of Jonzac, Rochefort, Avène, La Roche Posay, Uriage, Saint Gervais, Gamarde, Fumades, Cauteret, Evaux and Vichy, preferably the thermal spring water of Jonzac.

3. The composition according to claim 1 or 2, characterized in that The composition comprises thermal water in a concentration by weight of between 0.5% and 99.5%, preferably between 5% and 50%, more preferably between 10% and 35%, still more preferably 20% or 30% of the total weight of the composition.

4. The composition according to claim 1, characterized in that The Lactobacillus acidophilus extract is a Lactobacillus acidophilus cell lysate derived from Lactobacillus acidophilus fermentation.

5. The composition according to claim 1, characterized in that The composition comprises a Lactobacillus acidophilus extract in a concentration between greater than 1.5% and 10% by weight of the total weight of the composition, preferably between 2% and 10%, more preferably between 2% and 5%, even more preferably 2% by weight of the total weight of the composition.

6. Composition according to one of the preceding claims, characterized in that The composition further comprises, alone or in combination, hyaluronic acid and its derivatives; hydroxyproline and its derivatives, such as dipalmitoyl hydroxyproline; hydrolyzed lupin protein; algae extracts, such as aqueous extracts of protein-rich brown algae such as Fucus vesiculosus and Laminaria japonica, oily extracts of green algae such as Pterocarpus serrata or Chlorella vulgaris, or extracts of red algae such as Jania rubens; oligosaccharides (prebiotics); zinc PCA; mallow or chamomile flower water; witch hazel extract; Centella asiatica extract; aloe vera extract / aloe vera juice; ceramides, such as N-oleoyl-phytosphingosine (or ceramide NP); phytosphingosine; sodium carrageenan; dextrin; phytic acid; tocopherol; buckwheat wax; shea butter; castor oil; vegetable squalane; glycerin.

7. Composition according to one of the preceding claims, characterized in that The composition is in a form suitable for topical administration.

8. Composition according to one of claims 1 to 7, for protecting, strengthening and / or repairing the barrier function of the skin and reducing the discomfort of sensitive to reactive and even atopic skin.

9. Composition according to one of claims 1 to 7 for use in combating skin aging.

10. Composition according to one of claims 1 to 7 for improving the skin microflora.

Images